又一家跨国药企向和铂医药抛来橄榄枝！ 12月17日，和铂医药(股票代码：02142.HK)宣布与百时美施贵宝达成长期全球战略合作及许可协议，双 方将共同研发新一代多特异性抗体疗法。 和铂医药有望获得逾11亿美元付款 根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现项目。为此，和铂医药将 获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可获得高达10.35亿 美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。 百时美施贵宝是全球领先制药企业，也是首批进入中国的跨国制药企业，专注于肿瘤学、血液学、免疫 与纤维化及心血管疾病等领域的药物研发。近年来，该公司依托全球研发与商业化能力，持续推动创新 药从实验室走向临床应用，实现药物的临床价值及商业价值。 以Harbour Mice等核心技术平台为依托，和铂医药快速推动"抗体+"技术转化，已研发出20余款具有差 异化竞争优势的创新产品。其中，核心产品HBM9161于2021年获得国家药监局授予的"突破性治疗认 证"，并已递交上市申请。此外，其他多条差异化产品管线也在稳步推进中。 在人工智能赋能生物医药创 ...

Core Insights - Harbour BioMed has entered a multi-year global strategic collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies [1][2] - The agreement includes potential payments totaling $90 million and up to $1.035 billion in development and commercial milestones, along with tiered royalties [2] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company aims to build a robust portfolio through internal R&D, collaborations, and selective acquisitions [4] Technology and Innovation - The proprietary Harbour Mice technology platform generates fully human monoclonal antibodies in various formats, enhancing the therapeutic potential of biologics [5] - The HCAb-based immune cell engagers (HBICE) technology allows for tumor-killing effects that traditional therapies cannot achieve, making the antibody discovery engine unique and efficient [5] Strategic Collaboration - The collaboration with Bristol Myers Squibb is expected to leverage Harbour BioMed's technology and development capabilities, particularly in conducting early clinical trials in China [3]

Core Insights - Harbour BioMed has advanced its global strategic collaboration with AstraZeneca to develop next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers, leveraging both companies' expertise [1][3] Collaboration Details - AstraZeneca will nominate discovery programs to Harbour BioMed annually over the next four years, with the option to license these programs for further development. Harbour BioMed will receive option fees, milestone payments, and tiered royalties on future net sales [2] Company Background - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology, building a robust pipeline through internal R&D, strategic collaborations, and selective acquisitions [4] Technology Platform - The company utilizes its proprietary Harbour Mice technology to generate fully human monoclonal antibodies in various formats, enabling the development of innovative biologics for treating significant medical needs [5]

Core Insights - The article highlights the recognition of HAPO Pharmaceutical and its subsidiary Nona Bio for their innovative human-derived heavy chain antibody (HCAb) technology, which addresses the challenges of long development cycles, high costs, and significant risks in the biopharmaceutical industry [1][2] - HAPO's HCAb technology is seen as a key to unlocking the next generation of biopharmaceuticals, with advantages in molecular size, antigen recognition, and tissue penetration [2][4] - The company has established a flexible and diverse business model that enhances its competitive edge, attracting partnerships with major pharmaceutical companies like AstraZeneca and Pfizer [4][5] Technology and Innovation - HAPO's proprietary Harbour Mice platform is a rare human antibody development platform capable of generating both dual light chain (H2L2) and heavy chain (HCAb) monoclonal antibodies [2] - The HCAb Plus™ platform has been developed to support the creation of complex molecules such as bispecific antibodies and antibody-drug conjugates (ADCs) [2][5] - The company has launched an AI-assisted drug discovery engine, Hu-mAtrIx™, to accelerate antibody discovery across various therapeutic areas [7] Business Model and Partnerships - HAPO has successfully engaged in over ten licensing agreements with major pharmaceutical companies, leveraging a License-out model [4] - The NewCo model allows HAPO to deepen collaborations through joint ventures, exemplified by its partnership with Boston Children's Hospital [4] - A notable partnership with AstraZeneca includes a $4.575 billion deal and a $105 million equity investment, marking a shift from single transactions to strategic partnerships [4] Financial Performance - HAPO has achieved profitability in 2023 and 2024, with a reported net profit of approximately 523 million yuan in the first half of the year, reflecting a 51-fold year-on-year increase [5][8] - The company aims to become a global leader in antibody drug development, targeting a growth trajectory similar to that of Regeneron [7][8] Future Goals - HAPO's strategic focus is on "platform monetization + pipeline breakthroughs," with plans to solidify its position as a "new infrastructure" in global antibody drug development [7] - The company has developed over 20 innovative products with differentiated competitive advantages, including the core product HBM9161, which received breakthrough therapy designation from the National Medical Products Administration [7][8]

Core Viewpoint - The company, Heptares Therapeutics, is gaining significant attention in the competitive biopharmaceutical industry, particularly in the fields of immune diseases and oncology, following a remarkable 51-fold increase in net profit in the first half of the year and a substantial investment from Singapore's GIC [1][6]. Investment and Partnerships - GIC increased its stake in Heptares Therapeutics by investing approximately HKD 511 million to acquire 40.22 million shares, raising its ownership from 1.62% to 6.37% [2]. - GIC, managing over USD 800 billion, is recognized for its long-term value investment strategy, and its investment in Heptares is seen as a validation of the company's technological capabilities and commercial prospects [2]. - Heptares has established multiple collaborations with major pharmaceutical companies, including three significant partnerships with AstraZeneca, which highlight its growing influence in the global biopharmaceutical sector [4][5]. Technological Advancements - Heptares has developed proprietary antibody technology platforms, such as Harbour Mice, which can generate fully human monoclonal antibodies in various forms, enhancing its drug development capabilities [3]. - The company’s innovative products, including immune cell connectors and bispecific immune cell antagonists, are positioned to provide significant therapeutic benefits in oncology and inflammatory diseases [3]. Financial Performance - In the first half of 2025, Heptares reported total revenue of approximately CNY 725 million, a year-on-year increase of 327%, and a net profit of about CNY 523 million, reflecting a 51-fold increase [6]. - The company’s cash reserves reached approximately CNY 2.291 billion, a 92% increase from the end of the previous year, indicating strong financial health [6]. - Heptares has established a sustainable business model through innovative product licensing and partnerships, with over 40 collaborations and a potential total deal value exceeding USD 10 billion [6]. Future Prospects - Heptares plans to accelerate the development of innovative product pipelines targeting both new and known targets, with several clinical trials underway [7]. - The company aims to expand its platform capabilities into immune and inflammatory disease areas, leveraging its advanced drug discovery engines [7].

Core Viewpoint - The company, Heptagon Pharmaceuticals (和铂医药-B), experienced a significant stock price increase following the announcement of its interim financial results, reflecting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from licensing fees increased from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new product licenses [1] - Research services and technology licensing revenue rose by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - In March 2025, the company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation bispecific antibodies targeting immune diseases, tumors, and other conditions [1] - The collaboration includes the use of Heptagon's proprietary fully human antibody technology platform, Harbour Mice, for multiple projects across various therapeutic areas [1] - As part of this agreement, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), experienced a significant stock price increase following the release of its interim financial results, highlighting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from molecular licensing fees rose from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products [1] - Research services and technology licensing fee income increased by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - The company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation multispecific antibodies targeting immune diseases, tumors, and other conditions, set to commence in March 2025 [1] - The collaboration includes the use of the company's proprietary fully human antibody technology platform, Harbour Mice, across multiple therapeutic areas [1] - In return for this partnership, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]